Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Cerilliant
Julphar
Baxter
Teva
Chubb
Covington
Dow
Accenture

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021959

« Back to Dashboard

NDA 021959 describes ORAPRED ODT, which is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ORAPRED ODT profile page.

The generic ingredient in ORAPRED ODT is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
Pharmacology for NDA: 021959
Suppliers and Packaging for NDA: 021959
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-700 59212-700-48 8 BLISTER PACK in 1 CARTON (59212-700-48) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-701 59212-701-02 1 BLISTER PACK in 1 CARTON (59212-701-02) > 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 15MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 30MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021959

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ➤ Subscribe ➤ Subscribe
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ➤ Subscribe ➤ Subscribe
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Cantor Fitzgerald
Boehringer Ingelheim
Baxter
Accenture
Farmers Insurance
Argus Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot